Lung Cancer Diagnostic Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Lung Cancer Diagnostic Treatment Pipeline Review H2 2017

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Summary
Medical Devices sector report, “Lung Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2016" provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/815417-lung-cancer-diagnostic-tests-medical-devices-pipeline-assessment-2016

Scope
– Extensive coverage of the Lung Cancer Diagnostic Tests under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

Reasons to buy
The report enables you to –
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 12
1.2 List of Figures 23
2 Introduction 24
2.1 Lung Cancer Diagnostic Tests Overview 24
3 Products under Development 25
3.1 Lung Cancer Diagnostic Tests – Pipeline Products by Stage of Development 25
3.2 Lung Cancer Diagnostic Tests – Pipeline Products by Territory 26
3.3 Lung Cancer Diagnostic Tests – Pipeline Products by Regulatory Path 27
3.4 Lung Cancer Diagnostic Tests – Pipeline Products by Estimated Approval Date 28
3.5 Lung Cancer Diagnostic Tests – Ongoing Clinical Trials 29
4 Lung Cancer Diagnostic Tests – Pipeline Products under Development by Companies 30
4.1 Lung Cancer Diagnostic Tests Companies – Pipeline Products by Stage of Development 30
4.2 Lung Cancer Diagnostic Tests – Pipeline Products by Stage of Development 35
5 Lung Cancer Diagnostic Tests Companies and Product Overview 40
5.1 A&G Pharmaceutical Inc Company Overview 40
5.2 Abbott Diagnostics Company Overview 42
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/815417-lung-cancer-diagnostic-tests-medical-devices-pipeline-assessment-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

New York Corporate Whistleblower Center Now Urges an Employee with Significant Proof Their New York Based Employer Has Two Sets of Books to Avoid Tax Payment to Call About Rewards

Why sit on a winning lotto ticket and never know what it could have been worth?”

— New York Corporate Whistleblower

WASHINGTON, DC, USA, March 2, 2017 /EINPresswire.com/ — The New York Corporate Whistleblower Center says, "We are urging a bookkeeper, accountant or employee anywhere in New York State to call us anytime at 866-714-6466 if their employer/client is keeping two sets of books to avoid paying state income or sales taxes. The reward potential for this specific types of whistleblower can be significant so long as the company's non-reporting of income/sales taxes anywhere in New York State is at least $150,000 for each of the last three or four years. New York State is the only state in the nation with an aggressive initiative to reward whistleblowers who have proof of state sales tax or income tax fraud. The state can go back ten years and potential whistleblower rewards can range between 15% to 25% of what the state recovers. http://NewYork.CorporateWhistleblower.Com

The New York Corporate Whistleblower Center Is Urging employees of companies in New York to call them anytime at 866-714-6466 if they have proof their employer is running two sets of books-one set of books that does not include cash transactions-and a second set of accounting records/books that show all transactions. http://NewYork.CorporateWhistleblower.Com

The Center is especially interested in hearing from bookkeepers or employees of the following types of companies in New York if they can prove the company is involved in significant state income tax fraud:

* A Major home improvement or remodeling contractor
* An appliance dealer
* A Restaurant or Bar
* A roofing contractor or plumbing company
* A Car dealership or auto body company
* An Adult entertainment club that warehouses cash.
* Any type of business in New York State paying their employees cash because they are illegal aliens.
* A criminal enterprise such as a drug dealer/syndicate that warehouses large quantities of cash.
* Illegal gambling operations anywhere in New York State.

"If you are an employee of any kind of business in New York State, and you can prove your employer is keeping separate records for cash and non-cash to avoid the payment of taxes. Why sit on a winning lotto ticket and never know what it could have been worth? If you possess this type of information-please call us anytime at 866-714-6466 and allow us to explore the reward potential of your information." http://NewYork.CorporateWhistleblower.Com

Simple rules for a whistleblower from the New York Corporate Whistleblower Center: Do not go to the government first if you are a potential whistleblower with substantial proof of wrongdoing. The New York Corporate Whistleblower Center says, “Major whistleblowers frequently go to the government thinking they will help. It’s a huge mistake. Do not go to the news media with your whistleblower information. Public revelation of a whistleblower’s information could destroy any prospect for a reward. Do not try to force a company/employer or individual to come clean about significant Medicare fraud, overbilling the federal government for services never rendered, multi-million-dollar state or federal tax evasion, or a New York based company falsely claiming to be a minority owned business to get preferential treatment on federal or state projects. Come to us first, tell us what type of information you have, and if we think it’s sufficient, we will help you with a focus on you getting rewarded.” http://NewYork.CorporateWhistleblower.Com

Unlike any group in the US the Corporate Whistleblower Center can assist a potential whistleblower with packaging or building out their information to potentially increase the reward potential. They will also provide the whistleblower with access to some of the most skilled whistleblower attorneys in the nation. For more information a possible whistleblower with substantial proof of wrongdoing in New York can contact the Whistleblower Center at 866-714-6466 or contact them via their website at http://NewYork.CorporateWhistleBlower.Com.

Thomas Martin
New York Corporate Whistleblower Center
866-714-6466
email us here


Source: EIN Presswire

West Virginia Mesothelioma Victims Center Now Offers a Coal Miner or Navy Veteran in West Virginia Better Lawyer Options When It Comes to Financial Compensation Results

Call us at 800-714-0303 so at a minimum you know what lawyers nationwide get the best possible compensation results for their clients”

— West Virginia Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, March 2, 2017 /EINPresswire.com/ — The West Virginia Mesothelioma Victims Center is now offering a coal miner or US Navy Veteran in West Virginia who has been diagnosed with mesothelioma much better lawyer options when it comes to financial compensation results for the diagnosed person or their family. Before a person in West Virginia with mesothelioma hires a lawyer/law firm to assist with a financial compensation claim they are urged to first call the Center at 800-714-0303 for on the spot access to some of the nation's most skilled and experienced mesothelioma attorneys. http://WestVirginia.MesotheliomaVictimsCenter.Com

The Center says, "About a month ago-we were in Wheeling, West Virginia and we saw on a local TV station run a mesothelioma commercial from a one-man law firm in Houston, Texas appealing to people in West Virginia to call his 800-telephone number. Please do not call TV mesothelioma law firms. In most instances-they are marketing law firms that broker out people with mesothelioma as if they were a commodity.

"If we had one incredibly vital tip for a coal miner, a US Navy Veteran or anyone who has just been diagnosed with mesothelioma in West Virginia it would be call us at 800-714-0303 so at a minimum you know what lawyers nationwide get the best possible compensation results for their clients. Please don't shortchange yourself when it comes to mesothelioma compensation." http://WestVirginia.MesotheliomaVictimsCenter.Com

High risk work groups for exposure to asbestos in West Virginia include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, coal miners, manufacturing, or industrial workers, plumbers, electricians, auto mechanics, machinists, miners, or construction workers. Typically the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s, or 1980’s. http://WestVirginia.MesotheliomaVictimsCenter.Com

The West Virginia Mesothelioma Victims Center wants to emphasize their unsurpassed free services are available statewide to a diagnosed victim in any community in the Mountain State including Wheeling, Morgantown, Martinsburg, Charleston, Huntington, and Fairmont.

The West Virginia Mesothelioma Victims Center is also incredibly focused on making certain a diagnosed victim in the Mountain State has the best treatment options. Two of the better options for diagnosed victims in West Virginia include the Mary Babb Randolph Cancer Center in Morgantown, or the University of Pittsburgh’s Cancer Institute:

* The Mary Babb Randolph Cancer Center Morgantown, West Virginia :http://www.wvucancer.org/.#sthash.lf6xcXiQ.dpuf

* The University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania: http://upci.upmc.edu/

The average age for a diagnosed victim of mesothelioma is 72 years old. Frequently victims of mesothelioma are initially misdiagnosed with pneumonia. This year between 2500, and 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is attributable to exposure to asbestos.

The states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Michael Thomas
West Virginia Mesothelioma Victims Center
800-714-0303
email us here


Source: EIN Presswire

Bacterial Pneumonia Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Bacterial Pneumonia Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Summary
Pharmaceutical and Healthcare disease pipeline guide Bacterial Pneumonia – Pipeline Review, H2 2016, provides an overview of the Bacterial Pneumonia (Infectious Disease) pipeline landscape.
Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung’s air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris. This often impairs the body’s ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/854906-bacterial-pneumonia-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Bacterial Pneumonia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bacterial Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 8, 13, 2, 30, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 9 and 6 molecules, respectively.
Bacterial Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Bacterial Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bacterial Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bacterial Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Pneumonia (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bacterial Pneumonia (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bacterial Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ACCESS REPORT @ https://www.wiseguyreports.com/reports/854906-bacterial-pneumonia-pipeline-review-h2-2016

Table of Content: Key Points
Table of Contents 2
Introduction 5
Bacterial Pneumonia Overview 6
Therapeutics Development 7
Bacterial Pneumonia – Therapeutics under Development by Companies 9
Bacterial Pneumonia – Therapeutics under Investigation by Universities/Institutes 12
Bacterial Pneumonia – Pipeline Products Glance 13
Bacterial Pneumonia – Products under Development by Companies 17
Bacterial Pneumonia – Products under Investigation by Universities/Institutes 21
Bacterial Pneumonia – Companies Involved in Therapeutics Development 22
Bacterial Pneumonia – Therapeutics Assessment 65
Drug Profiles 75
Bacterial Pneumonia – Dormant Projects 185
Bacterial Pneumonia – Discontinued Products 190
Bacterial Pneumonia – Product Development Milestones 191
…Continued

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=854906

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Nicotine Addiction Consumption, Key Players and Forecast 2017 – 2022


Wise.Guy12

Wise.Guy.

Nicotine Addiction Market Consumption 2017 Forecast to 2022

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Summary
The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/393581-nicotine-addiction-pipeline-review-h1-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
– The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
– The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content: Key Points
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Nicotine Addiction Overview 7
Therapeutics Development 8
Pipeline Products for Nicotine Addiction – Overview 8
Pipeline Products for Nicotine Addiction – Comparative Analysis 9
Nicotine Addiction – Therapeutics under Development by Companies 10
Nicotine Addiction – Therapeutics under Investigation by Universities/Institutes 11
Nicotine Addiction – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nicotine Addiction – Products under Development by Companies 14
Nicotine Addiction – Products under Investigation by Universities/Institutes 15
Nicotine Addiction – Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Astraea Therapeutics, LLC 17
Cerecor Inc. 18
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/393581-nicotine-addiction-pipeline-review-h1-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Computer Aided Design (CAD) Market Research Report 2017 Analysis and Forecast to 2022

WiseGuyReports.com adds “Computer Aided Design (CAD) Market 2017 Global Analysis, Growth, Trends Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Computer Aided Design (CAD) Market:

Executive Summary

This report studies the global Computer Aided Design (CAD) market, analyzes and researches the Computer Aided Design (CAD) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Dassault Systemes
PTC
Nanosoft
VariCAD
Cadonix
Caddie Software
Menhirs NV
Kubotek USA
Autodesk
Siemens Product Lifecycle Management Software

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1015241-global-computer-aided-design-cad-market-size-status-and-forecast-2022

Market segment by Regions/Countries, this report covers

United States
EU
Japan
China
India
Southeast Asia

Market segment by Type, Computer Aided Design (CAD) can be split into

3-D Design
2-D Design

Market segment by Application, Computer Aided Design (CAD) can be split into

Mechanical Design
Architectural Design
Aviation Design
Other

Access Report @ https://www.wiseguyreports.com/reports/1015241-global-computer-aided-design-cad-market-size-status-and-forecast-2022

Table of Contents

Global Computer Aided Design (CAD) Market Size, Status and Forecast 2022
1 Industry Overview of Computer Aided Design (CAD)
1.1 Computer Aided Design (CAD) Market Overview
1.1.1 Computer Aided Design (CAD) Product Scope
1.1.2 Market Status and Outlook
1.2 Global Computer Aided Design (CAD) Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Computer Aided Design (CAD) Market by Type
1.3.1 3-D Design
1.3.2 2-D Design
1.4 Computer Aided Design (CAD) Market by End Users/Application
1.4.1 Mechanical Design
1.4.2 Architectural Design
1.4.3 Aviation Design
1.4.4 Other

2 Global Computer Aided Design (CAD) Competition Analysis by Players
2.1 Computer Aided Design (CAD) Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 Dassault Systemes
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 PTC
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Nanosoft
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 VariCAD
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Cadonix
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Caddie Software
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Menhirs NV
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Kubotek USA
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 Autodesk
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 Siemens Product Lifecycle Management Software
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Computer Aided Design (CAD) Revenue (Value) (2012-2017)
3.10.5 Recent Developments

4 Global Computer Aided Design (CAD) Market Size by Type and Application (2012-2017)
4.1 Global Computer Aided Design (CAD) Market Size by Type (2012-2017)
4.2 Global Computer Aided Design (CAD) Market Size by Application (2012-2017)
4.3 Potential Application of Computer Aided Design (CAD) in Future
4.4 Top Consumer/End Users of Computer Aided Design (CAD)

5 United States Computer Aided Design (CAD) Development Status and Outlook
5.1 United States Computer Aided Design (CAD) Market Size (2012-2017)
5.2 United States Computer Aided Design (CAD) Market Size and Market Share by Players (2016 and 2017)

6 EU Computer Aided Design (CAD) Development Status and Outlook
6.1 EU Computer Aided Design (CAD) Market Size (2012-2017)
6.2 EU Computer Aided Design (CAD) Market Size and Market Share by Players (2016 and 2017)

7 Japan Computer Aided Design (CAD) Development Status and Outlook
7.1 Japan Computer Aided Design (CAD) Market Size (2012-2017)
7.2 Japan Computer Aided Design (CAD) Market Size and Market Share by Players (2016 and 2017)

8 China Computer Aided Design (CAD) Development Status and Outlook
8.1 China Computer Aided Design (CAD) Market Size (2012-2017)
8.2 China Computer Aided Design (CAD) Market Size and Market Share by Players (2016 and 2017)

9 India Computer Aided Design (CAD) Development Status and Outlook
9.1 India Computer Aided Design (CAD) Market Size (2012-2017)
9.2 India Computer Aided Design (CAD) Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Computer Aided Design (CAD) Development Status and Outlook
10.1 Southeast Asia Computer Aided Design (CAD) Market Size (2012-2017)
10.2 Southeast Asia Computer Aided Design (CAD) Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
11.1 Global Computer Aided Design (CAD) Market Size (Value) by Regions (2017-2022)
11.1.1 United States Computer Aided Design (CAD) Revenue and Growth Rate (2017-2022)
11.1.2 EU Computer Aided Design (CAD) Revenue and Growth Rate (2017-2022)
11.1.3 Japan Computer Aided Design (CAD) Revenue and Growth Rate (2017-2022)
11.1.4 China Computer Aided Design (CAD) Revenue and Growth Rate (2017-2022)
11.1.5 India Computer Aided Design (CAD) Revenue and Growth Rate (2017-2022)
11.1.6 Southeast Asia Computer Aided Design (CAD) Revenue and Growth Rate (2017-2022)
11.2 Global Computer Aided Design (CAD) Market Size (Value) by Type (2017-2022)
11.3 Global Computer Aided Design (CAD) Market Size by Application (2017-2022)

12 Computer Aided Design (CAD) Market Dynamics
12.1 Computer Aided Design (CAD) Market Opportunities
12.2 Computer Aided Design (CAD) Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Computer Aided Design (CAD) Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Computer Aided Design (CAD) Market Driving Force
12.4.1 Growing Demand

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1015241

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Herbal Oil Market Product Type, Application And Specification And Forecast To 2022

This report is segmented into several key Regions,production, consumption,revenue, market share and growth rate of Herbal Oil in these regions from 2012 to 2022

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Global Herbal Oil Market

Global Herbal Oil market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Biolandes
Essential Oils of New Zealand
Farotti Essenze
Falcon
H.Reynaud & Fils (HRF)
The Lebermuth Company
Moksha Lifestyle Products
Young Living Essential Oils
Ungerer Limited
RK-Essential Oils
Meena Perfumery
TFS Corporation

Get Sample Report @ https://www.wiseguyreports.com/sample-request/1013391-global-herbal-oil-market-research-report-2017

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Orange
Citronella
Corn Mint
Eucalyptus
Lemon
Clove Leaf
Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Herbal Oil for each application, including
Food & Beverages
Pharmaceutical
Cosmetics & Personal Care Products
Spa & Salon Products
Household Cleaning Products
Others

Complete Report Details @ https://www.wiseguyreports.com/reports/1013391-global-herbal-oil-market-research-report-2017

Table of Contents -Major Key Points

Global Herbal Oil Market Research Report 2017
1 Herbal Oil Market Overview
1.1 Product Overview and Scope of Herbal Oil
1.2 Herbal Oil Segment by Type (Product Category)
1.2.1 Global Herbal Oil Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Herbal Oil Production Market Share by Type (Product Category) in 2016
1.2.3 Orange
1.2.4 Citronella
1.2.5 Corn Mint
1.2.6 Eucalyptus
1.2.7 Lemon
1.2.8 Clove Leaf
1.2.9 Others
1.3 Global Herbal Oil Segment by Application
1.3.1 Herbal Oil Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Food & Beverages
1.3.3 Pharmaceutical
1.3.4 Cosmetics & Personal Care Products
1.3.5 Spa & Salon Products
1.3.6 Household Cleaning Products
1.3.7 Others
1.4 Global Herbal Oil Market by Region (2012-2022)
1.4.1 Global Herbal Oil Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Herbal Oil (2012-2022)
1.5.1 Global Herbal Oil Revenue Status and Outlook (2012-2022)
1.5.2 Global Herbal Oil Capacity, Production Status and Outlook (2012-2022)

2 Global Herbal Oil Market Competition by Manufacturers
2.1 Global Herbal Oil Capacity, Production and Share by Manufacturers (2012-2017)
2.1.1 Global Herbal Oil Capacity and Share by Manufacturers (2012-2017)
2.1.2 Global Herbal Oil Production and Share by Manufacturers (2012-2017)
2.2 Global Herbal Oil Revenue and Share by Manufacturers (2012-2017)
2.3 Global Herbal Oil Average Price by Manufacturers (2012-2017)
2.4 Manufacturers Herbal Oil Manufacturing Base Distribution, Sales Area and Product Type
2.5 Herbal Oil Market Competitive Situation and Trends
2.5.1 Herbal Oil Market Concentration Rate
2.5.2 Herbal Oil Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Herbal Oil Capacity, Production, Revenue (Value) by Region (2012-2017)
3.1 Global Herbal Oil Capacity and Market Share by Region (2012-2017)
3.2 Global Herbal Oil Production and Market Share by Region (2012-2017)
3.3 Global Herbal Oil Revenue (Value) and Market Share by Region (2012-2017)
3.4 Global Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.5 North America Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.6 Europe Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.7 China Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.8 Japan Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.9 Southeast Asia Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.10 India Herbal Oil Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Herbal Oil Supply (Production), Consumption, Export, Import by Region (2012-2017)
4.1 Global Herbal Oil Consumption by Region (2012-2017)
4.2 North America Herbal Oil Production, Consumption, Export, Import (2012-2017)
4.3 Europe Herbal Oil Production, Consumption, Export, Import (2012-2017)
4.4 China Herbal Oil Production, Consumption, Export, Import (2012-2017)
4.5 Japan Herbal Oil Production, Consumption, Export, Import (2012-2017)
4.6 Southeast Asia Herbal Oil Production, Consumption, Export, Import (2012-2017)
4.7 India Herbal Oil Production, Consumption, Export, Import (2012-2017)

………..CONTINUED

Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1013391

CONTACT US :

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, Industryresearch reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Hypothyroidism Therapeutic and Symptoms Pipeline Review H2


Wise.Guy12

Wise.Guy.

Hypothyroidism Pipeline Review, H2 2017

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/794444-hypothyroidism-pipeline-review-h2-2016

The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 5 respectively.Hypothyroidism.

Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders).
– The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=794444

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Hypothyroidism Overview 6
Therapeutics Development 7
Pipeline Products for Hypothyroidism – Overview 7
Hypothyroidism – Therapeutics under Development by Companies 8
Hypothyroidism – Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Hypothyroidism – Products under Development by Companies 11
Hypothyroidism – Companies Involved in Therapeutics Development 12
Synthonics Inc 12
Titan Pharmaceuticals Inc 13
Hypothyroidism – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Target 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 21
(levothyroxine + liothyronine) – Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
BCT-305 – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
levothyroxine sodium SR – Drug Profile 23
Product Description 23
…Continued

Access Report @ https://www.wiseguyreports.com/reports/794444-hypothyroidism-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Spinal cord injury Symptoms and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Spinal cord injury Symptoms and Treatment Pipeline Review H2 2016

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/771890-spinal-cord-injury-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Spinal Cord Injury.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Spinal Cord Injury Overview 8
Therapeutics Development 9
Pipeline Products for Spinal Cord Injury – Overview 9
Pipeline Products for Spinal Cord Injury – Comparative Analysis 10
Spinal Cord Injury – Therapeutics under Development by Companies 11
Spinal Cord Injury – Therapeutics under Investigation by Universities/Institutes 14
Spinal Cord Injury – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Spinal Cord Injury – Products under Development by Companies 18
Spinal Cord Injury – Products under Investigation by Universities/Institutes 21
Spinal Cord Injury – Companies Involved in Therapeutics Development 22
AbbVie Inc 22
Acorda Therapeutics Inc 23
Asterias Biotherapeutics, Inc. 24
Asubio Pharma Co Ltd 25
Athersys Inc 26
BioArctic Neuroscience AB 27
BioAxone BioSciences Inc 28
Genervon Biopharmaceuticals LLC 29
Histocell SL 30
Kadimastem Ltd 31
Kringle Pharma Inc 32
Lpath Inc 33
MandalMed Inc 34
Mapreg SAS 35
Medgenics Inc 36
Neuralstem Inc 37
Neuronax SAS 38
New World Laboratories Inc 39
Omeros Corp 40
PharmatrophiX, Inc. 41
Pharmicell Co Ltd 42
Protagenic Therapeutics Inc. 43
…Continued
Access Report @ https://www.wiseguyreports.com/reports/771890-spinal-cord-injury-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Neuropathic Pain Diseases (Central Nervous System), Pharmaceutical and Healthcare Pipeline Review H2


Wise.Guy12

Wise.Guy.

Global Neuropathic Pain (Central Nervous System) Diseases and Treatment Pipeline Review H2 2017

PUNE, INDIA, March 2, 2017 /EINPresswire.com/ — Summary
Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.
Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/854907-neuropathic-pain-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 27, 29, 1, 119, 21 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.
Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ACCESS REPORT @ https://www.wiseguyreports.com/reports/854907-neuropathic-pain-pipeline-review-h2-2016

Table of Contents
Table of Contents 2
Introduction 8
Neuropathic Pain Overview 9
Therapeutics Development 10
Neuropathic Pain – Therapeutics under Development by Companies 12
Neuropathic Pain – Therapeutics under Investigation by Universities/Institutes 22
Neuropathic Pain – Pipeline Products Glance 24
Neuropathic Pain – Products under Development by Companies 28
Neuropathic Pain – Products under Investigation by Universities/Institutes 42
Neuropathic Pain – Companies Involved in Therapeutics Development 44
Neuropathic Pain – Therapeutics Assessment 165
Drug Profiles 188
Neuropathic Pain – Dormant Projects 491
Neuropathic Pain – Discontinued Products 516
Neuropathic Pain – Product Development Milestones 524
…Continued

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=854907

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire